trastuzumab-deruxtecan
3 clinical trials
1 product
41 abstracts
4 indications
Indication
Breast CancerIndication
Advanced CancerIndication
Metastatic CancerIndication
Advanced Solid TumorAbstract
Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.Org: LMU University Hospital Munich, Interdisciplinary Breast Center, Rotkreuz-Clinics Munich, West German Study Group, Ev. Hospital Bethesda,
Abstract
Defining low-HER2 cancers using RNA quantification by next generation sequencing.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack Medical Center, NJ, Genomic Testing Cooperative, Irvine,
Abstract
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.Org: Université de Montréal, McGill University Health Center, Department of Medical Oncology, Institut du Cancer de Montpellier, Institut de Génomique fonctionnelle, CNRS, University of MontpellierOncology, Institute of Oncology Ljubljana,
Abstract
Association of human epidermal growth factor receptor 2 expression with 21-gene recurrence score and survival among patients with estrogen receptor–positive breast cancer.Org: Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, University of Florida College of Medicine Jacksonville,
Abstract
Incidence of interstitial lung disease and cardiotoxicity with trastuzumab-deruxtecan in patients with breast cancer: A systematic review and single-arm meta-analysis.Org: Federal University of Goiás, Princess Margaret Hospital, Dona Íris Hospital and Maternity,
Abstract
Trastuzumab-deruxtecan in HER2-low metastatic/unresectable breast cancer: Real life data in two Parisian centers.Org: Hôpital Tenon, Institut Universitaire de Cancérologie, Sorbonne Université, APHP-INSERM U1149 Universite Paris Diderot, Hôpital La Pitié-Salpêtrière,
Product
Trastuzumab-deruxtecanAbstract
Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.Org: Sarah Cannon Research Institute/Tennessee Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.Org: Dana-Farber Cancer Institute, Yale School of Medicine, University of Pittsburgh Medical Center (UPMC), Yale Cancer Center, Harvard Medical School,
Abstract
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies.Org: University of California, San Francisco, Miami Cancer Institute, Baptist Health South Florida, Mayo Clinic, Rush University Medical Center,
Abstract
Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study.Org: Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy, Precision Medicine Unit in Senology Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy, Precision Medicine in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Fondazione Pascale, Naples, Italy, Sapienza University of Rome, Medical Oncology Department, Policlinico Umberto I, Roma, Italy,
Abstract
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).Org: The University of Texas MD Anderson Cancer Center, US Oncology Research/Maryland Oncology Hematology, Norton Healthcare, New York Presbyterian, Northwest Medical Specialties,
Abstract
Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03.Org: Vall d’Hebron University Hospital/VHIO, Vall d'Hebron Institute of Oncology, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group,
Abstract
Financial toxicity in patients with metastatic breast cancer on trastuzumab deruxtecan (T-DXd).Org: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, School of Social Work, The University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, NYU Grossman Long Island School of Medicine, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).Org: Maria Skłodowska-Curie National Research Institute and Oncology Centre, Hôtel-Dieu de Québec, Clinical Hospital “RZHD-Medicine”, Chi Mei Medical Center,
Abstract
Evaluating antitumor activity and response determinants to trastuzumab deruxtecan in pediatric solid tumors.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Mutational landscape of HER-2 low breast cancer.Org: University of California, San Francisco, UC Irvine Health, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, University of California, Irvine Medical Center,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.Org: Nantes University Hospital Center, Azienda Ospedaliero-Universitaria San Luigi Gonzaga,
Abstract
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors.Org: National Cancer Center East, Daiichi Sankyo Ltd.,
Abstract
Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies.Org: Samsung Medical Centre, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Memorial Sloan Kettering Cancer Center,
Abstract
Off-label use of fam-trastuzumab deruxtecan-nxki with early activity in a cohort of patients with desmoplastic small round cell tumor.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Interim safety analysis of phase IB trial of HER2 inhibitor tucatinib combined with PI3Kα inhibitor alpelisib in HER2+ PIK3CA-mutated metastatic breast cancer.Org: University of Colorado Health Cancer Care, University of Colorado Cancer Center, Louisiana State University Health Sciences Center Shreveport, University of Wisconsin, Mount Sinai Medical Center,
Abstract
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).Org: University of Milan and European Institute of Oncology, IRCCS, Fudan University Shanghai Cancer Center, Division of Medical Oncology, National Cancer Centre of Singapore, National Cancer Center Hospital East, Kashiwa, Japan, Latin American Cooperative Oncology Group (LACOG),
Abstract
A meta-analysis analyzing the efficacy of trastuzumab-deruxtecan (T-DXd) on central nervous system (CNS) disease in patients with metastatic breast cancer (mBC).Org: SUNY Upstate University Hospital, SUNY Upstate Medical University, SUNY Upstate Medical Center,
Abstract
A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC).Org: SUNY Upstate University Hospital, SUNY Upstate Medical University, SUNY Upstate Medical Center,
Abstract
Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC).Org: Syndax Pharmaceutials, Inc., Tariffville, CT,
Abstract
Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC).Org: Syndax Pharmaceuticals Inc.,
Clinical trial
Efficacy and Safety of T-Dxd in the Treatment of HER2-positive Breast Cancer With Brain Metastases After Prior Pyrotinib TreatmentStatus: Recruiting, Estimated PCD: 2023-12-30
Clinical trial
A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)Status: Recruiting, Estimated PCD: 2026-08-03
Clinical trial
A Phase 1, 2-Part, Multicenter, First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103a Combination Therapy in Subjects With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-06-30
Abstract
An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.Org: University Hospital Leuven, International Breast Cancer Centre (IBCC), Quironsalud Group, Aichi Cancer Center Hospital, Vall d’Hebron University Hospital/VHIO,
Abstract
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.Org: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Maria Sklodowska-Curie National Research Institute and Oncology Centre (MSCI), Warsaw, Poland, Hospital Clínico San Carlos and IdISSC, Madrid, Spain,
Abstract
Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).Org: Guardant Health, Inc., Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan,
Abstract
Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.Org: Memorial Sloan Kettering Cancer Center, Kanagawa Cancer Center, Severance Hospital, Hospital Clinic de Barcelona, Barcelona, Spain, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.Org: Daiichi Sankyo Co, Ltd., Daiichi Sankyo Inc.,
Abstract
HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering - Breast and Imaging Center, Lombardi Comprehensive Cancer Center, Georgetown University,
Abstract
Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer.Org: Stanford Hospital & Clinics, Department of Management Science and Engineering, Stanford University School of Medicine, Department of Health Policy,
Abstract
Association of pretreatment chest CT abnormalities with trastuzumab deruxtecan–associated pneumonitis.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Dana-Farber Cancer Institute,
Abstract
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.Org: Institut de Cancerologie de l'Ouest, Saint-Herblain, France, Gustave Roussy Cancer Center, ICO Institut de Cancerologie de l'Ouest, Oscar Lambret Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Angers, France,
Abstract
Analytical and clinical validation of Oncomine Dx Target (ODxT) test and local testing for identifying patients with HER2 (ERBB2)-mutant (HER2m) non–small-cell lung cancer (NSCLC) for treatment with trastuzumab deruxtecan (T-DXd) in DESTINY-Lung01/02 (DL-01/02).Org: Memorial Sloan Kettering Cancer Center, New York, NY, Netherlands Cancer Institute, Amsterdam, Netherlands, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children’s Oncology Group Pediatric Early-Phase Clinical Trial Network study.Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute, Institute for Clinical and Translational Research, Baylor College of Medicine, Baylor College of Medicine, Children's Oncology Group,
Abstract
Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution study.Org: University of California, Irvine, Irvine, CA, UC Irvine Health, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Nepal Medical College and Teaching Hospital, Kathmandu Medical College and Teaching Hospital,
Abstract
Development of a quantitative systems pharmacology (QSP) model to support dose optimization of DS-1103a (anti SIRPa antibody) in combination with trastuzumab deruxtecan in patients with cancer.Org: Daiichi Sankyo Inc., Certara Germany GmbH, Daiichi Sankyo Shinagawa R&D Center, Daiichi Sankyo Europe GmbH,
Abstract
Predictors of resistance to trastuzumab deruxtecan (T-DXd) in esophagogastric adenocarcinoma (EGC).Org: Weill Cornell Medical Center/New York Presbyterian, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering/Weill Cornell Medical College, Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center,
Abstract
ADC vs HP dual-antibody for HER2-positive advanced breast cancer after failed to TKI.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China, Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China, Department of Breast Cancer, the Fifth Medical Center Affiliated to PLA General Hospital, Beijing, China,